Envestnet Portfolio Solutions Inc. Acquires 23,240 Shares of Merck & Co., Inc. $MRK

Key Points

• Envestnet Portfolio Solutions increased its Merck stake by 28.3% in the second quarter, acquiring 23,240 shares and bringing its total holdings to 105,500 shares valued at approximately $13.6 million.
• Merck reported quarterly revenue of $16.61 billion, exceeding expectations and rising 5.1% year over year, while analysts maintained a “Moderate Buy” consensus with an average price target of $135.50.
• Investors face a mixed outlook: Merck offers a $0.85 quarterly dividend, but recent insider selling and long-term reliance on Keytruda—whose patent expiration could increase competitive pressure—remain risks.

Envestnet Portfolio Solutions Inc. increased its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 28.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 105,500 shares of the company's stock after acquiring an additional 23,240 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in Merck & Co., Inc. were worth $13,557,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Hager Investment Management Services LLC raised its holdings in shares of Merck & Co., Inc. by 0.9% in the 2nd quarter. Hager Investment Management Services LLC now owns 14,795 shares of the company's stock valued at $1,901,000 after purchasing an additional 132 shares during the period. Physician Wealth Advisors Inc. increased its holdings in shares of Merck & Co., Inc. by 2.3% in the second quarter. Physician Wealth Advisors Inc. now owns 4,682 shares of the company's stock valued at $602,000 after purchasing an additional 104 shares during the last quarter. Motive Wealth Advisors raised its position in shares of Merck & Co., Inc. by 10.7% in the second quarter. Motive Wealth Advisors now owns 2,473 shares of the company's stock valued at $318,000 after purchasing an additional 240 shares during the period. Sound Income Strategies LLC lifted its stake in shares of Merck & Co., Inc. by 3.6% during the 2nd quarter. Sound Income Strategies LLC now owns 4,917 shares of the company's stock worth $632,000 after buying an additional 172 shares during the last quarter. Finally, IFP Advisors Inc boosted its holdings in shares of Merck & Co., Inc. by 4.0% during the 2nd quarter. IFP Advisors Inc now owns 30,895 shares of the company's stock worth $3,970,000 after buying an additional 1,202 shares during the period. Institutional investors and hedge funds own 76.07% of the company's stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrade and higher valuations: Daiwa Securities upgraded MRK from “neutral” to “outperform” and set a $143 price target. Other analysts have raised fair-value estimates into the $140–$155 range, citing pipeline progress, business-development activity and late-stage therapies. Daiwa Securities upgrade
• Positive Sentiment: Business momentum remains supportive: MRK recently touched a record high, while Keytruda demand, oncology products, new launches and Animal Health helped drive quarterly revenue of $16.61 billion, above the $16.37 billion consensus estimate. The company also exceeded earnings expectations and reported 5.1% year-over-year revenue growth. Merck fair value and pipeline progress
• Positive Sentiment: Income and diversification appeal: Merck declared its regular $0.85 quarterly dividend, or $3.40 annualized, while potential expansion of ENFLONSIA for RSV prevention could broaden growth beyond oncology.
• Neutral Sentiment: Insider selling warrants monitoring: EVP Chirfi Guindo sold 10,000 shares for $1.35 million, following substantial sales by executives Jennifer Zachary and Richard Deluca. Each executive retained a meaningful stake, so the transactions may reflect personal financial decisions rather than a deteriorating outlook. Merck insider selling report
• Negative Sentiment: Keytruda concentration is a future risk: Patent expiration and increasing competition could pressure Merck’s largest growth driver. Investors will need evidence that the pipeline and newer products can offset eventual Keytruda sales declines. Keytruda growth outlook

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP David R. Maraldo sold 18,706 shares of the business's stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the transaction, the executive vice president owned 18,212 shares of the company's stock, valued at approximately $2,344,248.64. The trade was a 50.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Chirfi Guindo sold 15,000 shares of the firm's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $131.00, for a total value of $1,965,000.00. Following the completion of the sale, the executive vice president directly owned 46,613 shares in the company, valued at $6,106,303. This trade represents a 24.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

MRK has been the subject of several research reports. Bank of America raised their price objective on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a "buy" rating in a research report on Tuesday, June 30th. Wells Fargo & Company increased their target price on Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 8th. Morgan Stanley lifted their price target on Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an "equal weight" rating in a report on Thursday, July 9th. Daiwa Securities Group raised Merck & Co., Inc. from a "neutral" rating to an "outperform" rating and set a $143.00 price objective on the stock in a report on Wednesday. Finally, JPMorgan Chase & Co. boosted their target price on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an "overweight" rating in a research report on Monday, July 13th. Fifteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, Merck & Co., Inc. presently has a consensus rating of "Moderate Buy" and a consensus target price of $135.50.

Merck & Co., Inc. Stock Up 0.2%

MRK stock opened at $135.78 on Friday. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $135.97. The business has a 50-day simple moving average of $125.54 and a 200 day simple moving average of $119.94. The company has a quick ratio of 1.06, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The company has a market cap of $334.98 billion, a PE ratio of 108.62, a price-to-earnings-growth ratio of 5.85 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business's revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Sell-side analysts anticipate that Merck & Co., Inc. will post 2.77 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio (DPR) is 272.00%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source